Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings ...

Jahani-Asl’s team found evidence that the drug — called edaravone — shows promise in suppressing the self-renewing cancerous ...

The analyses offer evidence for a slowing of functional decline and improved survival outcomes with long-term Radicava ORS by ALS patients.

NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by ...

Edaravone dexborneol, a brain cell protection was used before EVT, and the proportion of patients with functional score 2 below 90 days was 55.0% vs. 49.6% compared with placebo, which was ...

Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS ...

No other ALS treatment appeared until 2017, when the FDA approved the novel antioxidant edaravone (Radicava). In 2022, the agency approved an oral suspension version, but a study published that ...